{"id":95796,"date":"2024-01-02T12:39:44","date_gmt":"2024-01-02T07:09:44","guid":{"rendered":"http:\/\/finservwealth.com\/alembic-pharma-shares-surge-5-on-usfda-product-approvals\/"},"modified":"2024-01-02T12:39:44","modified_gmt":"2024-01-02T07:09:44","slug":"alembic-pharma-shares-surge-5-on-usfda-product-approvals","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/alembic-pharma-shares-surge-5-on-usfda-product-approvals\/","title":{"rendered":"Alembic Pharma shares surge 5% on USFDA product approvals"},"content":{"rendered":"<p> Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.<\/p><div id=\"finse-2752054254\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/alembic-pharma-shares-surge-5usfda-product-approvals_17385941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments. Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/alembic-pharma-shares-surge-5usfda-product-approvals_17385941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/alembic-pharma-shares-surge-5usfda-product-approvals_17385941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments. Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/alembic-pharma-shares-surge-5usfda-product-approvals_17385941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-95796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/A\/ALEMBIC-PHARMA_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/95796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=95796"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/95796\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=95796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=95796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=95796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}